New 'Living Drug' trial offers hope for patients with incurable blood cancer
NCT ID NCT07510100
Summary
This early-stage study is testing a new type of personalized treatment called CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to better target the cancer, and then infuse them back into the patient. The main goals are to see if this one-time treatment is safe and if it can effectively reduce or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Science Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8519, Japan
Contact
-
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, 150-8935, Japan
Contact
-
Nihon University Itabashi Hospital
Itabashi-ku, Tokyo, 173-8610, Japan
Contact
Conditions
Explore the condition pages connected to this study.